Treatment of high-risk neuroblastoma in children: recent clinic trial results

Author(s): Emily Greengard,Christine Hill-Kayser,Rochelle Bagatell

Neuroblastoma is the most common extracranial solid tumor in childhood and accounts for 15% of all pediatric oncology deaths. Children with high-risk disease have a particularly poor prognosis, with nearly half succumbing to their disease despite aggressive multimodal therapy. A better understanding of the biological and clinical risk factors over the past few decades have led to significant breakthroughs and a series of clinical trials have improved outcomes for children with high-risk neuroblastoma. Despite this, many children will still die of their disease and novel approaches are desperately needed. The purpose of this review is to summarize the outcomes of recent clinical trials for children with high-risk neuroblastoma.